Stem Genomics–Clean Biologics: investment, 202606 acquisition €na of Stem Genomics by Clean Cells backed by Archimed

	Period	2026-06-18
	Money taker	Clean Cells SAS
	Group	Clean Biologics (CBX Holding) (Group)
	Product	iCS-digital PSC technology platform (Stem Genomics)
	Product 2	cell therapy manufacturing/processing technology

Clean Cells SAS. (6/18/26). "Press Release: Clean Cells Acquires Stem Genomics to Strengthen Cell Therapy Quality Control and Expand US Presence". Montaigu-Vendée, near Nantes.

Clean Cells, a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, today announces the acquisition of Stem Genomics, a provider of next-generation quality controls for stem cell therapy, including the company’s core asset, its iCS-digital PSC technology platform. This strategic purchase complements Clean Cells’ offerings as a GMP specialist for advanced cell therapies, enabling the company to provide clients with proprietary genomic stability testing designed specifically for the testing of human pluripotent stem cells (hPSCs).

Financial terms were not disclosed.

“Cell and gene therapy developers need reliable partners. With this deal, we are expanding our ability to support research teams from their early genomic stability testing through to cell banking and viral safety testing to GMP lot release. Stem Genomics brings its innovative proprietary technology, a strong US footprint and an expert team that understands stem cell biology at a level that takes years to build. This is the missing piece that completes our cell therapy quality control platform,” said Laurent Claisse, CEO of Clean Cells.

“Building Stem Genomics has taken years of dedication. What convinced us to join Clean Cells was simple: the people driving the group and a shared commitment to delivering the best quality genomic services. We built this company to help researchers trust their cell lines and with Clean Cells we can now follow those same clients all the way into the clinic. This is a critical next step for us,” said Nicolas Chapal, CEO of Stem Genomics, the company that he co-founded with Pr. John De Vos and Dr. Saïd Assou, researchers at the University of Montpellier, France.

“This acquisition highlights how we aim to build leaders in specialized life sciences services: with proprietary technology, regulatory expertise and the geographic reach to serve clients wherever they develop. Stem Genomics combined with Clean Cells’ GMP platform and KaryoLogic’s US presence now allows the Clean Biologics Group to cover the full quality control range for the fastest-growing segment of the biopharmaceutical market,” said Ludovic Alonzi, Partner at ARCHIMED, the healthcare-focused private equity firm and Clean Cell’s majority shareholder.

This acquisition by Clean Cells comes at a strategic time. The stem cell assay industry is projected to grow from $4.6 billion in 2025 to $10.27 billion by 2035, at a CAGR of 8.22%. iPSC-derived therapies also represent one of the fastest-growing areas in regenerative medicine, with programs targeting oncology, neurological disorders and rare diseases. At the same time, regulatory bodies around the world are increasingly requiring rigorous genomic integrity documentation before clinical use, driving developers to work with partners who can deliver genomic quality control that is both scientifically robust and scalable.

About Stem Genomics

Stem Genomics provides next-generation quality controls for cell therapy. It helps scientists assess the genomic stability of their cell lines with specific assays and recommended workflows for the cell type they work with. Today, Stem Genomics works with 150+ clients worldwide, from academic institutions to biotech companies and core facilities. Stem Genomics services North American clients from its laboratory based in the Research Triangle in Durham, North Carolina, and European and other international clients from its headquarters in Montpellier,
France.

www.stemgenomics.com

About ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and a financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

www.archimed.group

About Clean Cells

Clean Cells is a subsidiary of Clean Biologics. It offers (i) quality control and biological safety tests for biopharmaceutical products to assist in regulatory compliance, (ii) production of cell banks and GMP-grade BSL2/BSL3 virus seed stock, (iii) supply of secure storage for these products, alongside development and validation of bespoke analysis tools.

The company was created in 2000, when the co-founders received grants from the Aventis–Institut de France Foundation to offer innocuity testing for biopharmaceuticals. Clean Cells is now one of the largest European companies within this sector. Its strong customer focus and sizable product catalog (which expands annually) have made it a key player in the development of novel treatments and in personalized medicine. Clean Cells also stands out for its ability to react and adapt to its customers’ needs and the transparency of its production and quality control processes.

Clean Cells is headquartered near Nantes, in Western France, and operates in the United States through its subsidiary KaryoLogic Inc., located in Durham, North Carolina.

Clean Cells is an ARCHIMED Life Science Tools & Services company.

www.clean-cells.com

Media and analysts contacts

Andrew Lloyd & Associates

Saffiyah Khalique / Céline Gonzalez
saffiyah@ala.associates / celine@ala.associates
UK: +44 1273 952 481
US: +1 203 724 5950
@ALA_Group